BROOMFIELD, CO - Aclarion, Inc. (NASDAQ: ACON, ACONW), a healthcare technology firm, has announced findings from a study that could enhance the treatment of chronic low back pain (cLBP). The research, presented at the 50th International Society for the Study of the Lumbar Spine Annual Meeting 2024, utilized the company's Nociscan platform to investigate the role of Modic changes (MC) — MRI-detected spinal abnormalities — in cLBP.
The study conducted by the REACH Center at UCSF involved 88 patients with low back pain persisting for over three months. It aimed to clarify the biopsychosocial mechanisms of cLBP by examining the levels of propionic acid (PA), a metabolite of bacteria commonly found in disc infections, in patients with MC. The non-invasive measurement of PA using Magnetic Resonance Spectroscopy (MRS) and Nociscan could potentially inform more personalized treatments for cLBP.
Aclarion's Nociscan is the first SaaS platform supported by evidence to noninvasively differentiate between painful and nonpainful discs in the lumbar spine. It quantifies chemical biomarkers associated with disc pain and uses proprietary algorithms to assist physicians in locating the source of a patient's low back pain.
The study's findings suggest that the presence of PA might help determine why some patients with MC respond to treatment while others do not. This could lead to future research on treating cLBP patients with high PA levels with antibiotics to see if it improves clinical outcomes.
Ryan Bond, Aclarion's Chief Strategy Officer, expressed that the company aims to provide new noninvasive information for physicians to make better patient care decisions. He commended the UCSF team for their innovative research and looks forward to further developments.
Aclarion specializes in leveraging MRS, signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments, with a focus on the chronic low back pain market.
The study's results present a significant step in understanding and potentially treating cLBP, which affects millions globally. The information is based on a press release statement from Aclarion, Inc.
In other recent news, Aclarion, Inc. has initiated a $10 million at-the-market offering, entering into an agreement with Ascendiant Capital Markets. The company has the potential to sell up to this amount of its common stock, as per a recent filing with the Securities and Exchange Commission. Additionally, Aclarion has received approval from its shareholders for a reverse stock split, a strategic move that could occur within a year. The company has also raised $290,000 through a common stock sale and exchanged approximately $930,000 of outstanding debt for equity.
On the technological front, Aclarion has secured its 23rd U.S. patent, relating to techniques that enhance the quality of spectral data from Magnetic Resonance Spectroscopy exams. Ascendiant Capital has initiated coverage on Aclarion's stock, rating it a 'Buy'. Furthermore, three of the four largest private insurance payers in the UK have agreed to cover Aclarion's Nociscan platform, a tool designed to aid physicians in identifying the source of chronic low back pain. Aclarion has also entered into a strategic partnership with ATEC, a major spine implant company, to leverage pre-surgical data for improved patient outcomes. These are some of the recent developments for the company.
InvestingPro Insights
In light of Aclarion, Inc.'s (NASDAQ: ACON, ACONW) recent study findings, investors may be keen to understand the company's financial health and market performance. According to InvestingPro data, Aclarion holds a market capitalization of $1.6 million. This relatively small cap size reflects the company's niche position in the healthcare technology industry. Furthermore, the company's revenue for the last twelve months as of Q2 2024 stands at $0.05 million, with a significant decline of -35.23% in revenue growth during the same period. These figures suggest challenges in revenue generation and potential headwinds for the company.
One of the notable InvestingPro Tips for Aclarion is that the company holds more cash than debt on its balance sheet, which could provide some financial flexibility in its operations and research endeavors. However, another tip points out that Aclarion suffers from weak gross profit margins, with a -51.53% margin in the last twelve months as of Q2 2024. This could indicate cost management issues or pricing pressures within its market.
Investors should also note that the company's stock price has experienced a significant downturn, with a one-year total return of -96.79%. This performance may concern potential and current investors, reflecting the market's reaction to the company's financials and growth prospects.
For those interested in a deeper analysis, there are additional InvestingPro Tips available that could provide further insights into Aclarion's market position and financial outlook. These tips can be found on the InvestingPro platform, which offers a comprehensive analysis of the company's performance and future expectations.
As Aclarion continues to innovate in the treatment of chronic low back pain, keeping an eye on these financial metrics and expert tips could be crucial for investors interested in the company's growth trajectory and investment potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.